Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T84634 | ||||
Target Name | Cytochrome P450 26 (CYP26A1) | ||||
Type of Target |
Clinical trial |
||||
Drug Potency against Target | Rambazole | Drug Info | IC50 = 4 nM | ||
4-((+/-)-(1H-imidazol-1-yl)-(E)-methylretinoate | Drug Info | IC50 = 40 nM | [1] | ||
4-((+/-)-(1H-imidazol-1-yl)-(E)-retinoic acid | Drug Info | IC50 = 2.4 nM | [1] | ||
LIAROZOLE | Drug Info | IC50 = 7000 nM | [2] | ||
Rambazole | Drug Info | IC50 = 5 nM | [2] | ||
Action against Disease Model | Rambazole | Drug Info | Talarozole (R115866), a selective inhibitor of P450-mediated all-trans retinoic acid for the treatment of psoriasis and acne. Silencing of the CYP26B1 gene expression or reduction of CYP26B1 enzymatic activity by using siRNA or the inhibitor R115866, respectively, increased atRA-mediated signaling and resulted in decreased cell proliferation. The CYP26 inhibitor also inducedexpression of atRA-responsive genes. Therefore, atRA-induced CYP26 expression accelerated atRA inactivation in AOSMCs, giving rise to an atRA-CYP26 feedback loop. Inhibition of this loop with a CYP26inhibitor increased retinoid signaling. | [3] | |
References | |||||
REF 1 | Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and pros... J Med Chem. 2004 Dec 30;47(27):6716-29. | ||||
REF 2 | Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem. 2008 Sep 1;16(17):8301-13. | ||||
REF 3 | CYP26B1 plays a major role in the regulation of all-trans-retinoic acid metabolism and signaling in human aortic smooth muscle cells. J Vasc Res. 2011;48(1):23-30. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.